Cargando…

Pioneer of prostate cancer: past, present and the future of FOXA1

Prostate cancer is the most commonly diagnosed non-cutaneous cancers in North American men. While androgen deprivation has remained as the cornerstone of prostate cancer treatment, resistance ensues leading to lethal disease. Forkhead box A1 (FOXA1) encodes a pioneer factor that induces open chromat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teng, Mona, Zhou, Stanley, Cai, Changmeng, Lupien, Mathieu, He, Housheng Hansen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Higher Education Press 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815845/ https://www.ncbi.nlm.nih.gov/pubmed/32946061 http://dx.doi.org/10.1007/s13238-020-00786-8

Ejemplares similares

Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer
por: Zhou, Stanley, et al.
Publicado: (2020)

Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer
por: Gao, Shuai, et al.
Publicado: (2020)

FOXA1 mutations alter pioneering activity, differentiation, and prostate cancer phenotypes
por: Adams, Elizabeth J., et al.
Publicado: (2019)

FOXA1: A Pioneer of Nuclear Receptor Action in Breast Cancer
por: Seachrist, Darcie D., et al.
Publicado: (2021)

A quantitative metric of pioneer activity reveals that HNF4A has stronger in vivo pioneer activity than FOXA1
por: Hansen, Jeffrey L., et al.
Publicado: (2022)

FOXA1 in prostate cancer
por: Dong, Hui-Yu, et al.
Publicado: (2022)

Pioneer Factors FOXA1 and FOXA2 Assist Selective Glucocorticoid Receptor Signaling in Human Endometrial Cells
por: Whirledge, Shannon, et al.
Publicado: (2017)

Past and present women pioneers in biomedical science
por: Marks, Lara
Publicado: (2021)

The pioneer transcription factors Foxa1 and Foxa2 regulate alternative RNA splicing during thymocyte positive selection
por: Lau, Ching-In, et al.
Publicado: (2021)

TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells
por: Zhou, Feng, et al.
Publicado: (2019)

Pioneer transcription factor FoxA is positioned on hypersensitive nucleosomes at active enhancers
por: Iwafuchi-Doi, Makiko, et al.
Publicado: (2013)

Particle therapy for prostate cancer: The past, present and future
por: Ishikawa, Hitoshi, et al.
Publicado: (2019)

Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer
por: Jing, Xuan, et al.
Publicado: (2019)

Bookmarking by specific and nonspecific binding of FoxA1 pioneer factor to mitotic chromosomes
por: Caravaca, Juan Manuel, et al.
Publicado: (2013)

Changes at the nuclear lamina alter binding of pioneer factor Foxa2 in aged liver
por: Whitton, Holly, et al.
Publicado: (2018)

Comprehensive Genomic Analysis Reveals that the Pioneering Function of FOXA1 Is Independent of Hormonal Signaling
por: Glont, Silvia-E., et al.
Publicado: (2019)

Vaccines: past, present and future
por: Plotkin, Stanley A
Publicado: (2005)

Transposable Elements Are Co-opted as Oncogenic Regulatory Elements by Lineage-Specific Transcription Factors in Prostate Cancer
por: Grillo, Giacomo, et al.
Publicado: (2023)

Pre-marked chromatin and transcription factor co-binding shape the pioneering activity of Foxa2
por: Cernilogar, Filippo M, et al.
Publicado: (2019)

PBX1 Genomic Pioneer Function Drives ERα Signaling Underlying Progression in Breast Cancer
por: Magnani, Luca, et al.
Publicado: (2011)

Genome-wide analysis reveals positional-nucleosome-oriented binding pattern of pioneer factor FOXA1
por: Ye, Zhenqing, et al.
Publicado: (2016)

The Pioneer Transcription Factor Foxa2 Modulates T Helper Differentiation to Reduce Mouse Allergic Airway Disease
por: Yánez, Diana C., et al.
Publicado: (2022)

FOXA1 inhibits prostate cancer neuroendocrine differentiation
por: Kim, Jung, et al.
Publicado: (2017)

FOXA1 regulates alternative splicing in prostate cancer
por: Del Giudice, Marco, et al.
Publicado: (2022)

Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression
por: Cowper-Sal·lari, Richard, et al.
Publicado: (2012)

PSA and Beyond: The Past, Present, and Future of Investigative Biomarkers for Prostate Cancer
por: Tosoian, Jeffrey, et al.
Publicado: (2010)

RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition
por: Han, Wanting, et al.
Publicado: (2022)

Sequence logic at enhancers governs a dual mechanism of endodermal organ fate induction by FOXA pioneer factors
por: Geusz, Ryan J., et al.
Publicado: (2021)

OR33-06 Pioneer Factor Foxa2 Mediates Chromatin Conformation Changes In Ligand-dependent Activation Of FXR
por: Hao, Yi, et al.
Publicado: (2023)

Different chromatin-scanning modes lead to targeting of compacted chromatin by pioneer factors FOXA1 and SOX2
por: Lerner, Jonathan, et al.
Publicado: (2023)

CRISPR‐based knock‐in mutagenesis of the pioneer transcription factor FOXA1: optimization of strategies for multi‐allelic proteins in cancer cells
por: Li, Shen, et al.
Publicado: (2021)

Frequent mutation of the FOXA1 untranslated region in prostate cancer
por: Annala, Matti, et al.
Publicado: (2018)

Past, Present, and Future of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer
por: Mishra, Mona, et al.
Publicado: (2021)

Variant Set Enrichment: an R package to identify disease-associated functional genomic regions
por: Ahmed, Musaddeque, et al.
Publicado: (2017)

Ferroptosis: past, present and future
por: Li, Jie, et al.
Publicado: (2020)

Pioneer factor Foxa2 enables ligand-dependent activation of type II nuclear receptors FXR and LXRα
por: Kain, Jessica, et al.
Publicado: (2021)

Redistribution of lamina-associated domains reshapes binding of pioneer factor FOXA2 in development of nonalcoholic fatty liver disease
por: Wei, Xiaolong, et al.
Publicado: (2022)

Past, present and future
Publicado: (1982)

Past, present and future
Publicado: (2000)

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
por: Baca, Sylvan C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nprnvpbdmmhbj8rm4b5vl3ems0